Table 2. Correlation of overall and progression-free survival (Kaplan–Meier estimates, log-rank tests and Cox regression) according to stromal or cytoplasmic SPARC expression in the total study population, in the primary tumour and metastatic tissue subgroups and in the gemcitabine-based and fluoropyrimidine- based treatment subgroups.

	n	%	OS (months)	P (log-rank)	HR	95% CI	PFS (months)	P (log-rank)	HR	95% CI
Stromal SPARC
Total
High	90	67	9.1	0.316	0.823	0.562–1.205	7.0	0.314	1.254	0.805–1.953
Low	44	34	7.6				5.9
Primary tumour
High	46	72	10.8	0.857	0.948	0.528–1.701	8.6	0.792	1.099	0.543–2.224
Low	18	18	8.3				7.4
Metastasis
High	44	63	7.8	0.319	0.772	0.463–1.287	6.6	0.539	1.199	0.671–2.141
Low	26	37	6.8				4.1
Cytoplasmic SPARC
Total
Positive	74	55	7.8	0.032	1,505	1.034–2.190	6.2	0.004	1.878	1.208–2.921
Negative	60	45	8.4				8.6
Primary tumour
Positive	36	56	7.9	0.030	1,839	1.054–3.211	6.7	0.004	2.680	1.335–5.379
Negative	28	44	11.9				10.8
Metastasis
Positive	38	55	7.0	0.452	1,216	0.730–2.025	5.8	0.502	1.215	0.688–2.145
Negative	32	45	7.8				6.6
Gemcitabine subgroup
Stromal SPARC
High	72	62.5	9.9	0.180	0.762	0.499–1.141	7.8	0.192	1.379	0.848–2.242
Low	40	37.5	7.6				5.8
Cytoplasmic SPARC
Positive	60	53.6	7.3	0.012	1.693	1.114–2.560	6.2	0.002	2.158	1.319–3.531
Negative	52	46.4	9.9				9.2
Fluopyrimidine subgroup
Stromal SPARC
High	18	81.8	7.2	0.765	1.192	0.386–3.646	4.0	0.651	0.751	0.210–2.694
Low	4	18.2	4.0				2.2
Cytoplasmic SPARC
Positive	14	63.6	9.1	0.106	0.474	0.188–1.197	6.7	0.032	0.282	0.082–0.966
Negative	8	36.4	4.1				2.2

Abbreviations: CI=confidence interval; HR=hazard ratio; OS=(median) overall survival; PFS=(median) progression-free survival; SPARC=secreted protein acidic and rich in cysteins.